Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2015

View Archived Issues

Cerulean collaborates with GOG Foundation to study CRLX-101 with paclitaxel in ovarian cancer

ISA and Shin Nippon Biomedical to investigate nasal delivery of HPV16 vaccine

Addition of ipilimumab to Prostvac appears beneficial in treating prostate cancer

BMS gains option to license Prostvac from Bavarian Nordic

CTX conditioning maximizes SB-728-T engraftment

Encouraging results seen with TRC-105 and axitinib in renal cell carcinoma trial

Innocrin Pharmaceuticals presents encouraging data for VT-464

Durect highlights epigenomic regulator program and completion of phase I trial

Islet Sciences signs license agreement with Brighthaven Ventures for remogliflozin

Array BioPharma forms agreement with Novartis for binimetinib and encorafenib

Boston Scientific to acquire American Medical Systems' urology portfolio

Daktari closes series D funding round to support diagnostic platform

IlluminOss Medical enrolls first patient in humerus fracture repair trial

Loxo Oncology provides update on selected pipeline programs

NICE publishes guideline recommending photodynamic diagnosis to improve detection of bladder cancer

Novartis patents new MEK inhibitors

German researchers disclose glutathione peroxidase inhibitors

KU Leuven patents new antibiotics

Sun Pharma to buy GlaxoSmithKline's opiates business in Australia

Roche discloses RSV fusion inhibitors

Novogen's TRXE-009 shows potential for adult and pediatric brain cancer

First-in-human MesomiR 1 study results confirm tolerability of TargomiRs

RQx Pharmaceuticals reports new peptide antibiotics

AbbVie to acquire Pharmacyclics

FDA approves Opdivo for metastatic squamous NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...